StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
Teva Pharma
13.44
-0.41%
 

TEVA

 

Teva Pharma

$ 13.44

 
-$0.06 | -0.41%
 
 
Open
$ 13.58
 
 
MKT CAP
$ 14.61B
 
High
$ 13.62
 
 
VOL
$ 13.74M
 
Low
$ 13.25
 
 
AVG VOL
$ 12.59M
 
 
 

TEVA Stock Analysis

  Login to display Teva Pharma (TEVA) recommendation from the last 90 days from financial news and social media.
 
 

TEVA Total Score

 
 

Strengths

TEVA Rewards

 Upgraded on attractively valued

TEVA Rewards

 Investors confidence is positive

 

Risk Analysis

TEVA Risk Analysis

 Earnings are forecast to decrease

 
 

Chart

 
 

11.49

9.83

8.12

9.32

 
 
1month
3month
6month
1year
 
Total Return
TEVA
vs.
S&P500
 

 
1-week Return
+1.05%
 
+1.04%
 
 
5-week Return
+12.85%
 
+4.91%
 
 
10-week Return
+26.43%
 
+7.60%
 
 
 

TEVA Risk Level

This Indicator assigning TEVA risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
TEVA Risk Level
LOW
HIGH

Risk Volatility

 

TEVA has Low Risk Level

Click here to check what is your level of risk

 

TEVA Analysts Opinion

TEVA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

4.20
 

TEVA Earnings Sentiment

 Above analyst estimates

TEVA Earnings Sentiment

 Revenue increase YoY

 
 

Rating

×
 

Rating

4.75
 

TEVA Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

3.40
 

TEVA Momentum Analysis

 Has been gaining momentum

 

Activity

×
 

Activity

3.81
 

TEVA Activity Sentiment

 Investors confidence is positive

 

Future

×
 

Future

2.88
 

TEVA Future Sentiment

 Earnings are forecast to decrease

 
 

TEVA Analysts Opinion

TEVA Analysts opinion is positive and also has improved from the past 3 months

 

TEVA Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
82%
Buy
Opinion
Trend
Score
Potential
Score
 
 
100%
60%
50%
 
On Track
On Track
On Track
 

TEVA Street Opinion 

TEVA Street view is extremely ish but have mixed views on the near-term outlook

 

TEVA Performance Sentiment

Sentiments overview associated with TEVA events and the stock performance.
 
82%
13%
Positive
Negative
31 out of 38
events present
5 out of 38
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

TEVA Earnings

The TTM reflects 12-month period, providing review of TEVA financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
15,017
14,925
15,878
-2.75%
 
 
Cost of Revenue
8,200
7,952
8,284
-0.51%
 
 
Gross Profit
6,817
6,973
7,594
-5.25%
 
 
Operating Exp
4,267
4,283
4,495
-2.57%
 
 
Operating Inc
2,550
2,690
3,099
-9.29%
 
 
Net Interest Inc
-1,051
-966
-1,058
-
 
 
Interest Exp
990
966
1,058
-3.27%
 
 
Other Income
-3,602
-4,789
-1,384
-
 
 
EPS
-
-2.12
0.38
-
 
 
 
Similar to TEVA
Total Score
Close Price
%
Change

SNY

Sanofi

3.31

47.15

-0.30%

 

ALKS

Alkermes plc

3.60

29.92

-1.06%

 
 
 
Highlights
Last Modify
Price
% Change

 
Approvals
This Week
13.50
+2.66%
 
Agreements
This Week
13.29
+3.06%
 
Investors Buying
1 Week Ago
13.07
+0.35%
 
Upgrade
2 Weeks Ago
12.91
+7.40%
 
Strong Earnings
2 Month Ago
12.46
+2.89%
 
 
 
joker
 
 
 
StocksRunner

Explore our TEVA Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our TEVA Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

TEVA Rewards

 Upgraded on attractively valued

TEVA Rewards

 Investors confidence is positive

 

Risk Analysis

 

TEVA Risk Analysis

 Earnings are forecast to decrease

 
 
 

TEVA Risk Level

 
 
 

The Indicator assigning TEVA risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
TEVA Risk Level
LOW
HIGH

Risk Volatility

 

TEVA has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

TEVA

 

Teva Pharma

$ 13.44

 
-$0.06 | -0.41%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 13.58
 
 
MKT CAP
$ 14.61B
 
High
$ 13.62
 
 
VOL
$ 13.74M
 
Low
$ 13.25
 
 
AVG VOL
$ 12.59M
 
 
 

TEVA Analysis

  Sign in to view Teva Pharma (TEVA) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

11.49

9.83

8.12

9.32

 
 
1month
3month
6month
1year
 
Total Return
TEVA
vs.
S&P500
 

 
1-week Return
+1.05%
 
+1.04%
 
 
5-week Return
+12.85%
 
+4.91%
 
 
10-week Return
+26.43%
 
+7.60%
 
 
 

TEVA Analysts Opinion

TEVA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

4.20
 

TEVA Earnings Sentiment

 Above analyst estimates

TEVA Earnings Sentiment

 Revenue increase YoY

 
 

Rating

×
 

Rating

4.75
 

TEVA Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

3.40
 

TEVA Momentum Sentiment

 Has been gaining momentum

 

Activity

×
 

Activity

3.81
 

TEVA Activity Sentiment

 Investors confidence is positive

 

Future

×
 

Future

2.88
 

TEVA Future Sentiment

 Earnings are forecast to decrease

 
 

TEVA Analysts Opinion

TEVA Analysts opinion is positive and also has improved from the past 3 months

 

TEVA Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
82%
Buy
Opinion
Trend
Score
Potential
Score
 
 
100%
60%
50%
 
On Track
On Track
On Track
 

TEVA Street Opinion 

TEVA Street view is extremely ish but have mixed views on the near-term outlook

 
TEVA Performance Sentiment
Sentiments overview associated with TEVA events and the stock performance.
 
82%
13%
Positive
Negative
31 out of 38
events present
5 out of 38
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

TEVA Earnings

The TTM data reflects the most recent 12-month period, providing overview of TEVA financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
15,017
14,925
15,878
-2.75%
 
 
Cost of Revenue
8,200
7,952
8,284
-0.51%
 
 
Gross Profit
6,817
6,973
7,594
-5.25%
 
 
Operating Exp
4,267
4,283
4,495
-2.57%
 
 
Operating Inc
2,550
2,690
3,099
-9.29%
 
 
Net Interest Inc
-1,051
-966
-1,058
-
 
 
Interest Exp
990
966
1,058
-3.27%
 
 
Other Income
-3,602
-4,789
-1,384
-
 
 
EPS
-
-2.12
0.38
-
 
 
Highlights
Last Modify
Price
% Change

 
Approvals
This Week
13.50
+2.66%
 
Agreements
This Week
13.29
+3.06%
 
Investors Buying
1 Week Ago
13.07
+0.35%
 
Upgrade
2 Weeks Ago
12.91
+7.40%
 
Strong Earnings
2 Month Ago
12.46
+2.89%
 
 
TEVA Latest News Feed

UroGen falls as Teva seeks FDA nod for Jelmyto generic.

Fri Mar 1, 2024

Activity
Momentum

Teva and Jiangsu announce partnership for distribution of AUSTEDO in China.

Mon Feb 26, 2024

Activity

Alvotech/Teva win FDA approval for Humira biosimilar.

Mon Feb 26, 2024

Activity

Alvotech and Teva Announce United States Approval of SIMLANDI® (adalimumab-ryvk) injection the first interchangeable high-concentration citrate-free biosimilar to Humira®. REYKJAVIK Iceland and PARSIPPANY N.J. Feb. 24 2024 (GLOBE NEWSWIRE) -- Alvotech

Sat Feb 24, 2024

Activity

TEVA Quantitative Stock Analysis. Below is Valideas guru fundamental report for TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR) (TEVA). Of the 22 guru strategies we follow TEVA rates highest using our Acquirers Multiple Investor model based on the pub

Tue Feb 20, 2024

Potential

Teva Pharma CEO Dismisses Split Speculations Expects Significant Interest For Its API Business Divestiture: Report. As previously speculated) will not undergo a split into two separate entities. On Tuesday Teva’.s Chief Executive However the compan

Tue Feb 20, 2024

Activity

Teva Pharmaceuticals Announces Positive Data For Anti-TL1A Asset. (RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) Tuesday announced positive results for its anti-TL1A or TEV-574 asset a human monoclonal antibody targeting TL1A which can b

Tue Feb 20, 2024

Activity

Why This Teva Pharmaceutical Analyst Is Turning ish On The Austedo Franchise. Shares of ) climbed in early trading on Monday . The stock seems poised for a recovery due to the Austedo franchise the improved positioning of the United States generics busin

Mon Feb 12, 2024

Activity
Momentum
Potential

Teva upgraded to Overweight at Piper Sandler on multiple expansion.

Mon Feb 12, 2024

Activity
Rating
Rating

Beyond The Numbers: 8 Analysts Discuss Teva Pharmaceutical Indus Stock. Throughout the last three months 8 analysts have evaluated Teva Pharmaceutical Indus (NYSE:) offering a diverse set of opinions from ish to bearish. The table below provides a snapsh

Mon Feb 12, 2024

Potential

sheins top United States lawyer departs. shein lawyers have plenty of work on their plate right now as the china-founded fast-fashion firm fends off a raft of trademark infringement lawsuits and gears up for a potential United States initial public offeri

Mon Feb 5, 2024

Activity

teva q4 earnings and revenues surpass estimates stock up. teva pharmaceutical industries limited teva reported fourth-quarter 2023 adjusted earnings of $1 per share which beat the zacks consens

Thu Feb 1, 2024

Earnings
Momentum

teva pharmaceutical non-gaap eps of $1.00 beats by $0.24 revenue of $4.46b beats by $450m.

Wed Jan 31, 2024

Earnings

teva hits 52-week high on outlook api divestment.

Wed Jan 31, 2024

Momentum

teva pharma guides fy24 revenue above estimates. intends to divest api business - update. (rttnews) - while reporting financial results for the fourth quarter on wednesday teva pharmaceutical industries ltd (teva) initiated its adjusted earnings

Wed Jan 31, 2024

Earnings

teva pharm profit handily beats q4 estimates sales jump. teva pharmaceutical industries reported sharply higher fourth-quarter profit helped by higher sales and an upfront payment from sanofi as part of its collaboration to develop a treatment f

Wed Jan 31, 2024

Activity
Earnings

teva pharm sees lower 2024 profit after large q4 beat. teva pharmaceutical industries forecast lower profit in 2024 after a strong 2023 fourth quarter which benefited from a large upfront payment from sanofi as part of its collaboration to devel

Wed Jan 31, 2024

Activity

generic drug player teva pharma to divest its active pharmaceutical ingredient business q4 earnings surpass estimates. ) reported fourth-quarter 2023 sales of $4.46 billion beating the. this increase was mainly due to an upfront payment of $500 million i

Wed Jan 31, 2024

Earnings

check out what whales are doing with teva. high-rolling investors have positioned themselves bearish on teva pharmaceutical indus (nyse:) and it'.s important for retail traders to take note. \this activity came to our attention today through benzinga

Mon Jan 29, 2024

Potential
Potential

teva crosses above average analyst target. in recent trading shares of teva pharmaceutical industries ltd (symbol: teva) have crossed above the average analyst 12-month target price of $11.88 changing hands for $11.99/share. when a stock reache

Wed Jan 24, 2024

Potential
Potential

teva raised to buy at jefferies citing a positive setup ahead of 2024 outlook.

Tue Jan 23, 2024

Rating

teva pharmaceutical industries limited (teva) presents at j.p. morgan 42nd annual global healthcare conference (transcript).

Tue Jan 9, 2024

Activity

teva completes enrollment for schizophrenia drug trial.

Tue Jan 9, 2024

Activity

teva- pharmaceutical industries ltd. - adr shares climb 0.2% past previous 52-week high - market mover. teva- pharmaceutical industries ltd. - adr (teva) shares closed 0.2% higher than its previous 52 week high giving the company a market cap of

Mon Jan 8, 2024

Momentum

 
 
 
 
 

Score Tracker

 
 
 
Based on 38 events in the last 90 days from financial news and social media. Last updated Mar 4, 2024 16:31 Wall St. time
 
 

TEVA Total Score

 
 
 
 
 

Similar to TEVA

 
 
 
Symbol
Score
% Change

SNY

Sanofi

3.31

-0.30%

47.15

 

ALKS

Alkermes plc

3.60

-1.06%

29.92

 
 
 
 
 
 
StocksRunner

Discover TEVA Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of TEVA. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our TEVA Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

TEVA Stock trends

TEVA Stock performance

TEVA Stock analysis

TEVA investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker